Regenerative medicine company Orthocell (ASX:OCC) has announced the appointment of Leslie Wise, JD, as executive director.
Managing director, Paul Anderson, said, “We are delighted to welcome Leslie to the Orthocell Board. Leslie has extensive experience in securing US market access and reimbursement for medical devices as well as serving in various senior management positions across large US medical device and pharmaceutical companies. Leslie’s depth of knowledge and expertise is ideally suited to our product range and the next phase of growth for Orthocell.”
Ms Wise has extensive experience working for both medical device and pharmaceutical companies, including Bristol Myers-Squib, Sanofi, Biomet Orthopedics and AngioDynamics.
The company said, "This has helped her to hone a valuable skillset in reimbursement, value evidence generation, clinical research strategy and frontline regulatory and payer experience. She has demonstrated experience in strategically integrating outcomes research, health policy analysis, payer insight, patient preference, along with stakeholder engagement – and has been instrumental in creating new standards for reimbursement in the medtech space."
“I am very excited to be joining Orthocell at this pivotal stage in the company’s development. Orthocell has one of the most advanced musculoskeletal regenerative medicine portfolios globally, and is poised to leverage its impressive clinical evidence to drive towards the US, EU and AUS markets," said Ms Wise.
"The timing could not be better for Orthocell as the broader Orthopaedic sector moves towards biologics and minimally invasive surgeries to deliver higher quality, more efficient and cost-effective solutions.”
She is currently the Principal of EvidenceMatters, a global market access consultancy.